This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_INSITU_SKIN_LOWERLIMB_EXALLC for full statistics.
Carcinoma in situ of skin of lower limb, including hip
CD2_INSITU_SKIN_LOWERLIMB
No definition available.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions None
392423
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D04.7&
Hospital discharge: ICD-9
2327
Cause of death: ICD-10
D04.7&
Cause of death: ICD-9
2327
2 out of 7 registries used, show all original rules.
423
Check minimum number of events None
423
Include endpoints None
423
Remove individuals based on genotype QC
405
CD2_INSITU_SKIN_LOWERLIMB
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D04
Name in latin
Carcinoma in situ cutis pelvis
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of skin of lower limb, including hip
based on the number of shared cases.
Broader endpoints:
- Carcinoma in situ of skin of lower limb, including hip (controls excluding all cancers)
- Neoplasms
- Any event in hilmo or specialist outpatient
- Any ICDMAIN event in hilmo or causes of death
- Any prescribed medicine buy
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 405 | 238 | 167 |
| Unadjusted prevalence (%) | 0.11 | 0.11 | 0.10 |
| Mean age at first event (years) | 73.52 | 72.32 | 75.25 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_INSITU_SKIN_LOWERLIMB – Carcinoma in situ of skin of lower limb, including hip
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Carcinoma in situ of skin of lower limb, including hip
↥Endpoint not on priority list, no data to show.